For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Performance & Growth Hormone · Comparison

CJC-1295 + GHRP-6 Stack vs Hexarelin

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

CJC-1295 + GHRP-6 StackHexarelin
CategoryPerformance & Growth HormonePerformance & Growth Hormone
Also known asCJC GHRP-6 combination, GH releasing stack, GHRH GHRP combination, CJC-1295 GHRP-6Examorelin, EP 23905, MF-6003
EvidenceResearch-stagePreclinical only
Dosing rangeCJC-1295 100mcg + GHRP-6 100mcg–CJC-1295 200mcg + GHRP-6 300mcg mcg, 1–3x daily (pre-sleep, pre-workout, morning)50mcg–200mcg mcg, 1–3x daily (cycling recommended to prevent desensitization)
AdministrationSubcutaneous injectionSubcutaneous injection, Intramuscular injection
Key side effectsStrong appetite stimulation (GHRP-6 dominant effect), Water retention, Tingling / numbness in extremities, Mild cortisol elevation (GHRP-6 is less selective than ipamorelin)Cortisol elevation, Prolactin elevation, Water retention, Increased appetite
Cited sources2 references1 reference

Key differences

  • Evidence level differs: CJC-1295 + GHRP-6 Stack is research-stage, while Hexarelin is preclinical only.
  • Administration: CJC-1295 + GHRP-6 Stack — Subcutaneous injection; Hexarelin — Subcutaneous injection, Intramuscular injection.
  • Frequency: CJC-1295 + GHRP-6 Stack is typically 1–3x daily (pre-sleep, pre-workout, morning); Hexarelin is 1–3x daily (cycling recommended to prevent desensitization).
  • Research depth: this profile cites 2 sources for CJC-1295 + GHRP-6 Stack vs 1 for Hexarelin.

How each works

CJC-1295 + GHRP-6 Stack

The GHRH + GHRP combination synergistically amplifies GH pulse amplitude compared to either agent alone. CJC-1295 elevates baseline GH via GHRH receptor signaling at the pituitary; GHRP-6 triggers pulse timing via GHS-R1a. GHRP-6's potent appetite stimulation (significantly stronger than ipamorelin) makes this combination preferred in protocols targeting caloric surplus and mass accumulation.

Hexarelin

Hexarelin produces dose-dependent GH release significantly greater than GHRP-6 or Ipamorelin. It also has direct cardioprotective effects via CD36 receptor binding, independent of GH — making it unique among GHRPs. Studies show protection from ischemic cardiac injury and myocardial fibrosis reduction in animal models. Desensitization occurs with chronic continuous use.

Read the full CJC-1295 + GHRP-6 Stack profileRead the full Hexarelin profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.